

TIME TO REFOCUS

Insights into providing renal protection with SGLT2 inhibitors for patients with and without T2D

Wednesday, June 29th 2022
12:30–13:30 BST

ExCel London – Hall 17



Learning Objectives

- Highlight the importance of identifying and managing kidney disease (CKD) early
- Identify patients at high risk of renal function decline and recognize the steps required for screening and managing these patients early
- Interpret the data around the kidney and cardiovascular protective effects of SGLT2 inhibitors in patients with renal function decline, with or without Type 2 diabetes
- Apply pragmatic use of SGLT2 inhibitors in patients with renal function decline for kidney and cardiovascular protection

Session

Speaker

Welcome and introductions

Kamlesh Khunti



Identifying CKD in your practice

Kamlesh Khunti

The case for prioritising CKD

Ana Cebrián



Old news, myths, and latest data.
What you need to know before
initiating an SGLT2 inhibitor

Pam Kushner



Interactive discussion and Q&A

All faculty

Close

Kamlesh Khunti